Marshall Wace LLP Buys New Shares in biote Corp. (NASDAQ:BTMD)

Marshall Wace LLP purchased a new position in shares of biote Corp. (NASDAQ:BTMD - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 87,913 shares of the company's stock, valued at approximately $543,000. Marshall Wace LLP owned about 0.16% of biote at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Commonwealth Equity Services LLC acquired a new stake in shares of biote in the 4th quarter valued at approximately $68,000. Intech Investment Management LLC acquired a new stake in biote in the fourth quarter worth $71,000. SG Americas Securities LLC acquired a new stake in biote in the fourth quarter worth $76,000. Thompson Davis & CO. Inc. bought a new position in shares of biote during the fourth quarter worth $77,000. Finally, Wells Fargo & Company MN grew its holdings in shares of biote by 49.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,742 shares of the company's stock valued at $79,000 after buying an additional 4,243 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Craig Hallum dropped their price objective on biote from $12.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, March 13th.

biote Trading Up 4.0 %

Shares of NASDAQ:BTMD traded up $0.13 during trading on Tuesday, hitting $3.38. 1,169,374 shares of the company's stock traded hands, compared to its average volume of 192,547. The company has a 50-day moving average price of $3.66 and a 200-day moving average price of $4.97. biote Corp. has a 52 week low of $3.04 and a 52 week high of $8.44. The company has a market cap of $184.92 million, a price-to-earnings ratio of 13.00 and a beta of 1.17.

Insider Buying and Selling at biote

In related news, major shareholder Guines Llc acquired 750,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average cost of $3.22 per share, for a total transaction of $2,415,000.00. Following the completion of the acquisition, the insider now directly owns 3,820,938 shares in the company, valued at approximately $12,303,420.36. The trade was a 24.42 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Stephen Mark Cone bought 38,104 shares of biote stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $3.88 per share, with a total value of $147,843.52. Following the completion of the purchase, the director now owns 160,829 shares in the company, valued at approximately $624,016.52. This trade represents a 31.05 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 976,043 shares of company stock valued at $3,176,710. 24.00% of the stock is currently owned by corporate insiders.

biote Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.